CureVac N.V. $CVAC Shares Bought by Deutsche Bank AG

Key Points

• Deutsche Bank AG increased its stake in CureVac N.V. by 35.9%, owning 230,813 shares valued at approximately $639,000, according to its recent SEC filing.
• Several institutional investors have recently adjusted their stakes in CureVac, contributing to a total institutional ownership of 17.26%.
• Analysts have issued mixed ratings for CureVac, with an average target price of $6.83 and most firms rating the stock as a "hold".

Deutsche Bank AG boosted its stake in shares of CureVac N.V. (NASDAQ:CVAC - Free Report) by 35.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 230,813 shares of the company's stock after purchasing an additional 60,941 shares during the quarter. Deutsche Bank AG owned approximately 0.10% of CureVac worth $639,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. GSA Capital Partners LLP purchased a new position in shares of CureVac in the 1st quarter valued at about $853,000. BNP Paribas Financial Markets purchased a new position in shares of CureVac in the 4th quarter valued at about $585,000. Two Sigma Investments LP purchased a new position in shares of CureVac in the 4th quarter valued at about $391,000. Alyeska Investment Group L.P. increased its holdings in shares of CureVac by 25.0% in the 4th quarter. Alyeska Investment Group L.P. now owns 500,000 shares of the company's stock valued at $1,705,000 after acquiring an additional 100,000 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of CureVac by 98.1% in the 4th quarter. Northern Trust Corp now owns 60,100 shares of the company's stock valued at $205,000 after acquiring an additional 29,759 shares during the last quarter. Hedge funds and other institutional investors own 17.26% of the company's stock.

CureVac Stock Performance

Shares of NASDAQ CVAC remained flat at $5.37 during trading hours on Friday. The company had a trading volume of 321,215 shares, compared to its average volume of 646,154. CureVac N.V. has a 1 year low of $2.37 and a 1 year high of $5.72. The business's fifty day simple moving average is $5.43 and its 200-day simple moving average is $4.21. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.16 and a current ratio of 6.17. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of 5.59 and a beta of 2.53.

CureVac (NASDAQ:CVAC - Get Free Report) last posted its quarterly earnings data on Thursday, August 21st. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.15). CureVac had a return on equity of 29.57% and a net margin of 38.21%.The company had revenue of $1.41 million for the quarter, compared to analyst estimates of $4.27 million. On average, equities analysts predict that CureVac N.V. will post 0.72 EPS for the current year.

Analyst Ratings Changes

CVAC has been the topic of a number of recent analyst reports. Citizens Jmp downgraded CureVac from a "strong-buy" rating to a "hold" rating in a report on Thursday, June 12th. Jefferies Financial Group reiterated a "hold" rating and issued a $5.00 price objective (down previously from $7.00) on shares of CureVac in a report on Friday, June 13th. JMP Securities reissued a "market outperform" rating and issued a $10.00 target price on shares of CureVac in a research report on Wednesday, May 28th. Citigroup cut CureVac to a "market perform" rating in a research report on Thursday, June 12th. Finally, UBS Group cut CureVac from a "strong-buy" rating to a "neutral" rating and decreased their target price for the company from $12.00 to $5.50 in a research report on Thursday, June 26th. One investment analyst has rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $6.83.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.